ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech. IQVIA Biotech will provide patient recruitment, clinical monitoring, medical writing and biostatistics for ASLAN?s upcoming 300-patient Phase 2b trial of ASLAN004 in adults with moderate-to-severe atopic dermatitis. IQVIA Biotech will work closely with ASLAN?s management to oversee clinical operations and the recruitment of patients across sites in the United States, Canada, Europe and Asia. IQVIA Biotech is also positioned to collaborate with ASLAN?s clinical operations team on the future development plans for ASLAN003 in inflammatory bowel disease (IBD), with clinical trials commencing early next year. Enrollment of the first patient in the ASLAN004 Phase 2b trial is expected in the fourth quarter of 2021.